Characteristics of 66 patients with MF in the MPD-RC 101 study
| . | Sibling donor (n = 32) . | Unrelated donor (n = 34) . | |
|---|---|---|---|
| Diagnosis | |||
| PMF | 14 (44%) | 25 (74%) | |
| PV-MF | 3 (9%) | 5 (15%) | |
| ET-MF | 15 (47%) | 4 (12%) | |
| Lille score | |||
| 0 | 3 (9%) | 0 (0%) | |
| 1 | 20 (63%) | 23 (68%) | |
| 2 | 9 (28%) | 11 (32%) | |
| Age at transplant (y), median (range) | 55 (40-65) | 56 (30-65) | |
| Gender | |||
| Female | 13 (41%) | 15 (44%) | |
| Male | 19 (59%) | 19 (56%) | |
| Time from diagnosis (mo), median (range) | 16.1 (1-247) | 20 (2-341) | |
| Patient:donor gender | |||
| Female:Female | 6 (19%) | 7 (21%) | |
| Male:Male | 7 (22%) | 8 (24%) | |
| Male:Female | 10 (31%) | 6 (18%) | |
| Female:Male | 9 (28%) | 13 (38%) | |
| Age-adjusted DIPSS | |||
| Low | 5 (16%) | 5 (15%) | |
| Int-1 | 13 (41%) | 14 (41%) | |
| Int-2 | 8 (29%) | 10 (29%) | |
| High | 3 (9%) | 2 (6%) | |
| Unknown | 3 (9%) | 3 (9%) | |
| WBC ×109/L, median (range) | 5.1 (2-43) | 6.8 (1.3-70) | |
| Circulating blasts %, median (range) | 1.0 (0-10) | 0.12 (0-16) | |
| Platelets ×109/L, median (range) | 104 (28-927) | 120 (19-1662) | |
| JAK-2 V617F | |||
| Positive | 12 (38%) | 18 (53%) | |
| Negative | 17 (53%) | 16 (47%) | |
| Unknown | 3 (9%) | 0 (0%) | |
| Bone marrow fibrosis | |||
| Grade 1 | 0 | 2 (6%) | |
| Grade 2 | 2 (6%) | 6 (18%) | |
| Grade 3 | 18 (56%) | 23 (68%) | |
| Unknown | 12 (38%) | 3 (9%) | |
| Splenomegaly | |||
| Yes | 24 (75%) | 28 (82%) | |
| No | 3 (9%) | 1 (3%) | |
| Splenectomy | 5 (16%) | 5 (15%) | |
| Karyotype | |||
| Normal | 14 (44%) | 14 (41%) | |
| One abnormality | 7 (22%) | 9 (26%) | |
| Complex abnormality | 5 (16%) | 0 (0%) | |
| Unknown | 6 (19%) | 11 (32%) | |
| Stem cell source | |||
| Peripheral blood | 26 (81%) | 31 (91%) | |
| BM | 6 (19%) | 3 (9%) | |
| CD34 cells (×106/kg), PBSC median (range) | 5.9 (3.2-14) | 6.5 (2.9-11) | |
| TNC (×108/kg), BM median (range) | 3.7 (2.6-7.8) | 2.3 (1.9, 2.7) | |
| Full HLA matched | 30 (94%) | 25 (74%) | |
| HLA 1 Ag mismatched, no allele mismatched | 2 (6%) | 4 (12%) | |
| HLA Ag matched, 1 or 2 alleles mismatched | 0 (0%) | 5 (15%) | |
| . | Sibling donor (n = 32) . | Unrelated donor (n = 34) . | |
|---|---|---|---|
| Diagnosis | |||
| PMF | 14 (44%) | 25 (74%) | |
| PV-MF | 3 (9%) | 5 (15%) | |
| ET-MF | 15 (47%) | 4 (12%) | |
| Lille score | |||
| 0 | 3 (9%) | 0 (0%) | |
| 1 | 20 (63%) | 23 (68%) | |
| 2 | 9 (28%) | 11 (32%) | |
| Age at transplant (y), median (range) | 55 (40-65) | 56 (30-65) | |
| Gender | |||
| Female | 13 (41%) | 15 (44%) | |
| Male | 19 (59%) | 19 (56%) | |
| Time from diagnosis (mo), median (range) | 16.1 (1-247) | 20 (2-341) | |
| Patient:donor gender | |||
| Female:Female | 6 (19%) | 7 (21%) | |
| Male:Male | 7 (22%) | 8 (24%) | |
| Male:Female | 10 (31%) | 6 (18%) | |
| Female:Male | 9 (28%) | 13 (38%) | |
| Age-adjusted DIPSS | |||
| Low | 5 (16%) | 5 (15%) | |
| Int-1 | 13 (41%) | 14 (41%) | |
| Int-2 | 8 (29%) | 10 (29%) | |
| High | 3 (9%) | 2 (6%) | |
| Unknown | 3 (9%) | 3 (9%) | |
| WBC ×109/L, median (range) | 5.1 (2-43) | 6.8 (1.3-70) | |
| Circulating blasts %, median (range) | 1.0 (0-10) | 0.12 (0-16) | |
| Platelets ×109/L, median (range) | 104 (28-927) | 120 (19-1662) | |
| JAK-2 V617F | |||
| Positive | 12 (38%) | 18 (53%) | |
| Negative | 17 (53%) | 16 (47%) | |
| Unknown | 3 (9%) | 0 (0%) | |
| Bone marrow fibrosis | |||
| Grade 1 | 0 | 2 (6%) | |
| Grade 2 | 2 (6%) | 6 (18%) | |
| Grade 3 | 18 (56%) | 23 (68%) | |
| Unknown | 12 (38%) | 3 (9%) | |
| Splenomegaly | |||
| Yes | 24 (75%) | 28 (82%) | |
| No | 3 (9%) | 1 (3%) | |
| Splenectomy | 5 (16%) | 5 (15%) | |
| Karyotype | |||
| Normal | 14 (44%) | 14 (41%) | |
| One abnormality | 7 (22%) | 9 (26%) | |
| Complex abnormality | 5 (16%) | 0 (0%) | |
| Unknown | 6 (19%) | 11 (32%) | |
| Stem cell source | |||
| Peripheral blood | 26 (81%) | 31 (91%) | |
| BM | 6 (19%) | 3 (9%) | |
| CD34 cells (×106/kg), PBSC median (range) | 5.9 (3.2-14) | 6.5 (2.9-11) | |
| TNC (×108/kg), BM median (range) | 3.7 (2.6-7.8) | 2.3 (1.9, 2.7) | |
| Full HLA matched | 30 (94%) | 25 (74%) | |
| HLA 1 Ag mismatched, no allele mismatched | 2 (6%) | 4 (12%) | |
| HLA Ag matched, 1 or 2 alleles mismatched | 0 (0%) | 5 (15%) | |
Patients who received a stem cell transplant from a sibling (n = 32) or an unrelated (n = 34) donor were enrolled. Patients at low risk were enrolled only if they were thrombocytopenic.
Ag, antigen; BM, bone marrow; TNC, total nucleated cells; WBC, white blood cell.